MiniMed has announced FDA clearance of MiniMed Fit, the company's first tubeless insulin pump, bringing its automated insulin delivery (AID) technology to a new wearable design. The system offers up to seven days of wear and holds up to 300 units of insulin. MiniMed Fit is cleared for people with type 1 and type 2 diabetes ages 7 and older, with a phased U.S. launch expected to begin in spring 2027.
The clearance marks a major milestone for MiniMed as it enters the growing tubeless insulin pump market, offering an alternative to traditional insulin pumps that require tubing and the only other tubeless pump currently on the market, Omnipod.
One of the biggest draws of MiniMed Fit is its 300-unit insulin capacity and up to seven days of wear, potentially reducing how often users need to replace their insulin pumps. For comparison, Omnipod 5 holds up to 200 units of insulin and is designed for up to three days of wear. This gives MiniMed Fit 50% more insulin capacity and more than twice the potential wear time. However, MiniMed says the full seven-day wear duration is achievable for users who require fewer than 42 units of insulin per day. Those who use more insulin may need to replace the pump sooner. All other tubeless pumps launching next year also hold up to 200 units.

MiniMed Fit worn on the arm. (Source: MiniMed)
MiniMed Fit will use the same SmartGuard algorithm as MiniMed Flex and MiniMed 780G. SmartGuard automatically adjusts insulin delivery and can administer correction doses every five minutes based on glucose readings. The system also features MiniMed's Meal Detection technology, which can automatically deliver additional insulin when a meal bolus is missed or underestimated. However, users are still encouraged to bolus before meals for optimal glucose management.
At launch, MiniMed Fit will be compatible with two continuous glucose monitors (CGMs): MiniMed's Simplera Sync, which offers up to seven days of wear, and Instinct, a CGM developed by Abbott that lasts up to 15 days. The system can be controlled through a smartphone app on compatible iOS and Android devices, allowing users to manage insulin delivery directly from their phones.
How Does MiniMed Fit Work?
MiniMed Fit uses a two-piece design consisting of a disposable insulin-containing component and a reusable, rechargeable pump component. The disposable portion holds up to 300 units of insulin and includes the infusion set that lasts up to seven days. The rechargeable portion contains the pump's reusable electronics and is designed to be used across multiple pump changes. Users will receive two rechargeable pump components, allowing them to alternate between devices as needed.
We got a full demo of MiniMed Fit when we spoke with an executive on the podcast, you can watch that episode here.

The reusable piece gets charged and connected to each disposable pod. (Source: MiniMed)
MiniMed Fit can be worn on the abdomen, back of the upper arm, thigh, lower back, or upper buttocks, giving users flexibility in where they place the pump. However, MiniMed recommends that children and teenagers ages 7–17 wear the pump on the upper arm or thigh for the best wear duration.
MiniMed Fit is waterproof up to 8 feet (2.4 meters) for 1 hour and 45 minutes, allowing users to keep it on while showering or swimming within those limits. Keep in mind that AID systems can lose connection while underwater.
More Tubeless Insulin Pumps Are Coming in 2027
For years, Insulet has dominated the U.S. tubeless insulin pump market, with Omnipod 5 currently the only commercially available tubeless automated insulin delivery system. However, that's changing in 2027, with three new tubeless insulin pump options preparing to enter the market: MiniMed Fit, Mint, and Tandem's tubeless Mobi.
One of the biggest differences between these systems is how long they can be worn before needing to be replaced. Both Omnipod 5 and Mint hold up to 200 units of insulin and are designed for up to three days of wear, with Mint offering an additional 12-hour grace period and Omnipod 5 providing an additional eight hours before insulin delivery stops.
Tandem's newly cleared tubeless Mobi system also offers up to seven days of infusion-site wear, but there's an important distinction. Unlike MiniMed Fit, Tandem's tubeless Mobi requires users to replace its 200-unit insulin cartridge every three days, even though the infusion site can remain in place for up to a week.
This makes MiniMed Fit the only FDA-cleared tubeless insulin pump designed to operate for up to seven consecutive days without requiring a cartridge change, pump replacement, or charging, provided the user's insulin needs allow for the full wear duration. You can read more about Tandem's new system in our coverage of the tubeless Mobi FDA clearance.
When Will MiniMed Fit Be Available?
MiniMed says it expects to begin a phased U.S. rollout of MiniMed Fit in spring 2027, following an initial customer experience phase. The company plans to expand manufacturing capacity as commercialization progresses to meet anticipated demand.
MiniMed Fit will be available through the pharmacy channel, potentially making it easier for eligible users to access the system through their prescription benefits. While access may be easier for some, MiniMed says it may take more time for people with Medicare or Medicaid to have it covered by their plan. Pricing and insurance coverage details have not yet been announced.
What do you think about MiniMed Fit? Will you try it out? Let us know in the comments.
To hear more about what I think of MiniMed Fit, check out my blog post unpacking my first impressions of the device available to All Access members. Also, stay tuned for another blog post highlighting all the new details of MiniMed Fit and how I think it will compete with the other pumps and compare the size with my 3D-printed model. That post will be out later this week for those with an All Access membership.

